Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Norihiko Shiraishi"'
Autor:
Takamasa Hirai, Ken Kono, Shinji Kusakawa, Satoshi Yasuda, Rumi Sawada, Akihiko Morishita, Shinko Hata, Atsushi Wakita, Takayasu Kageyama, Ryo Takahashi, Sono Watanabe, Norihiko Shiraishi, Yoji Sato
Publikováno v:
Regenerative Therapy, Vol 21, Iss , Pp 540-546 (2022)
Introduction: Contamination of human cell-processed therapeutic products (hCTPs) with tumorigenic/immortalized cellular impurities is a major concern in the manufacturing and quality control of hCTPs. The cellular immortality test based on cell growt
Externí odkaz:
https://doaj.org/article/e9d27fb61bcb42359e4bdeae71d42de3
Publikováno v:
Annals of Forest Research, Vol 60, Iss 1, Pp 145-159 (2017)
We describe the development of a simulation based on neighbor relationships between small stands forming many sub compartments in a forested area. We used a Geographic Information System (GIS) to simulate local forest management plans. The distributi
Externí odkaz:
https://doaj.org/article/a5f7806764c04d338fc624ee342409d1
Autor:
Hiroshi Umehara, Yoshimi Maekawa, Fumito Koizumi, Makiko Shimizu, Toshio Ota, Tamer M. Fouad, Jie Willey, Hidekuni Kaito, Norihiko Shiraishi, Daisuke Nakashima, Shiro Akinaga, Naoto T. Ueno
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Background: KW-2450 is an oral dual insulin-like growth factor-1 receptor/insulin receptor tyrosine kinase inhibitor. We investigated the in vitro and in vivo preclinical activity of KW-2450 plus lapatinib and letrozole and conducted a phase I trial
Externí odkaz:
https://doaj.org/article/e78fa8802280460695e1175fa5a25353
Publikováno v:
Japanese Journal of Forest Planning. 51:57-67
Publikováno v:
Japanese Journal of Forest Planning. 49:75-81
Autor:
Hidekuni Kaito, Daisuke Nakashima, Toshio Ota, Jie Willey, Shiro Akinaga, Fumito Koizumi, Hiroshi Umehara, Naoto T. Ueno, Makiko Shimizu, Tamer M. Fouad, Norihiko Shiraishi, Yoshimi Maekawa
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Background:KW-2450 is an oral dual insulin-like growth factor-1 receptor/insulin receptor tyrosine kinase inhibitor. We investigated the in vitro and in vivo preclinical activity of KW-2450 plus lapatinib and letrozole and conducted a phase I trial o
Autor:
Umehara, Hiroshi, Maekawa, Yoshimi, Fumito Koizumi, Shimizu, Makiko, Ota, Toshio, Fouad, Tamer M., Willey, Jie, Hidekuni Kaito, Norihiko Shiraishi, Nakashima, Daisuke, Akinaga, Shiro, Ueno, Naoto T.
Supplemental material, KW-2450_TherAdvMedOncol_Additional_file_5Apr2018 for Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole by Hiroshi Umehara, Yoshimi Maeka
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e5a0355b09c488a68f5e6fcb8a291b
Publikováno v:
New Zealand Journal of Forestry Science. 47
Maximising forest profitability is important from both economic and ecological perspectives. Managers of forest areas gain utility by optimising profits, and maximising the efficiency of a forest stand is also beneficial to the natural environment. T
Timber growth functions by site index class (a), planting costs (b), harvesting cost functions (c) and timber prices (d) derived from previous studies (Nakajima et al. 2010; Nakajima et al. 2011a; Nakajima et al. 2011b; Nakajima et al. 2011d; Oka 200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c65734dfbfe03755e4a2f095769aecb6
Publikováno v:
Journal of Forest Planning. 18:21-27